AI smart T-shirt heart monitoring could spot hidden inherited heart rhythm disorders before they strike
Researchers at Imperial College London are developing an AI-powered smart T-shirt that continuously records heart electrical signals to detect hidden inherited rhythm disorders, aiming to catch intermittent abnormalities missed by short ECGs and prevent sudden cardiac deaths.
- Continuous monitoring: A wearable T-shirt with up to 50 woven ECG-style sensors records weeks of heart data.
- AI analysis: Machine learning reviews long-term traces to flag patterns linked to inherited rhythm disorders.
- Trials ahead: Training on >1,000 ECGs and a ~200-person feasibility study will test detection, comfort and practicality.
Why short ECGs miss dangerous conditions
Standard clinic ECGs are brief snapshots. Most common problems are visible in a few minutes, but many inherited heart rhythm disorders are intermittent — they appear and disappear. If the ECG is taken during a quiet interval, the trace can look normal even when risk is present. Clinicians call this a diagnostic blind spot.
Portable home monitors use adhesive electrodes and wires and are accurate but often impractical for long-term wear: patients must remove them to shower and reapply electrodes. That inconvenience reduces long-term data collection outside hospitals. Sources include Imperial College London news and the British Heart Foundation release.
How the AI smart T-shirt works
The shirt is made like sportswear with up to 50 slim ECG-style sensors woven into soft fabric so it can be worn under clothing, slept in, and washed. It records electrical heart signals continuously for days or longer.
After data capture, artificial intelligence analyzes long-term patterns to spot subtle or brief abnormalities — including signs associated with conditions such as Brugada syndrome. Weeks of tracing give clinicians context that a one-off ECG cannot provide. See the project overview at Imperial College London.
AI training and real-world testing
Researchers will train the algorithm on ECGs from more than 1,000 people, including individuals with known inherited rhythm disorders and those without, helping the AI learn what is normal versus concerning.
A feasibility study will invite about 200 volunteers to wear the shirt for up to three months at Hammersmith Hospital’s Peart-Rose Research Unit to evaluate detection outside hospitals, comfort, and daily practicality. If trials and regulatory reviews proceed favorably, researchers estimate potential clinical use in roughly five years. (Sources: Imperial College London; British Heart Foundation.)
What the experts say
“Far too many people die from inherited heart conditions which could be treated if identified earlier … Our AI-assisted t-shirt will provide a practical and comfortable solution for longer-term scanning,” said Professor Zachary Whinnett, project lead at Imperial.
Professor James Leiper, research director at the British Heart Foundation, added the project will “leverage AI to help clinicians unmask these hidden conditions and identify patients at risk of sudden death.” (Sources: Imperial College London news; British Heart Foundation.)
Funding, safety and regulatory steps
The project has received more than £340,000 from the British Heart Foundation and support from the NIHR Imperial Biomedical Research Centre. Researchers emphasize the shirt must pass thorough safety testing, regulatory review, accuracy validation, and checks to limit false alarms before routine clinical use.
Investigations will examine battery life, data storage and access, privacy protections, costs, and insurance coverage—matters that will shape adoption and trust among cautious, safety-minded audiences.
How this differs from current home monitors
Existing home ECG devices rely on adhesive electrodes and separate monitors; users often disconnect them to shower or change clothes, reducing continuous wear. The T-shirt is designed to be less intrusive and wearable for long stretches, increasing the chance of catching intermittent, otherwise-hidden abnormalities. See related coverage at MedicalXpress.
Practical concerns and questions
Investigators acknowledge open questions: battery longevity, secure data storage and access, cost and insurance frameworks (particularly in the U.S.), and the potential for false positives that could trigger unnecessary tests. Researchers say these issues will be addressed during clinical trials and regulatory review to protect patients and families.
For readers focused on personal responsibility and safety, the project aims to provide clinicians with better tools to identify risks early—and it will require clear rules on privacy, data security, and cost before wide use.
Implications for Alamogordo, New Mexico
Economic impact: If cleared in five years, local clinics and cardiology services could adopt the technology, prompting investment in equipment, staff training, and opportunities for local vendors and home-health providers.
Political consequences: Policymakers will face decisions about regulation and reimbursement—whether Medicare, Medicaid, and private insurers will cover prolonged wearable monitoring. Conservative preferences for private innovation balanced with clear safety standards are likely to shape debate.
Social and cultural effects: Early detection could reduce sudden deaths among young people, protecting families in Alamogordo and military communities at Holloman AFB. The T-shirt’s practicality aligns with local values of self-reliance and family protection.
Practical applications: Local doctors might prescribe the smart T-shirt for patients with family histories of inherited heart problems, unexplained fainting, or intermittent symptoms. Providers will need guidance on interpreting AI-generated flags and following up on risk signals.
Sources and links
- Imperial College London news
- Imperial College London: AI T-shirt article
- British Heart Foundation news
- MedicalXpress coverage
- Fox News coverage
Investigative notes
Reporting is based on Imperial College London and the British Heart Foundation releases and related coverage. No conflicting details were found in February 2026 announcements. The project remains in early trials; clinical use depends on trial outcomes and regulatory approval. Researchers emphasize patient safety, privacy, and rigorous testing as the initiative progresses.
